JP2018524347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524347A5 JP2018524347A5 JP2017568243A JP2017568243A JP2018524347A5 JP 2018524347 A5 JP2018524347 A5 JP 2018524347A5 JP 2017568243 A JP2017568243 A JP 2017568243A JP 2017568243 A JP2017568243 A JP 2017568243A JP 2018524347 A5 JP2018524347 A5 JP 2018524347A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- administered
- pharmaceutical composition
- compound
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940126062 Compound A Drugs 0.000 claims description 31
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 26
- 229960003301 nivolumab Drugs 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 238000000034 method Methods 0.000 description 76
- 201000005787 hematologic cancer Diseases 0.000 description 13
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 229940045513 CTLA4 antagonist Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 7
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 208000007660 Residual Neoplasm Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000011987 methylation Effects 0.000 description 3
- 238000007069 methylation reaction Methods 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 239000012270 PD-1 inhibitor Substances 0.000 description 2
- 239000012668 PD-1-inhibitor Substances 0.000 description 2
- 239000012271 PD-L1 inhibitor Substances 0.000 description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229940121655 pd-1 inhibitor Drugs 0.000 description 2
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 229950010773 pidilizumab Drugs 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 208000017726 ALK-positive large B-cell lymphoma Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000025316 Richter syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- GUWXKKAWLCENJA-WGWHJZDNSA-N [(2r,3s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl [(2r,3s,5r)-5-(4-amino-2-oxo-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical group O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)C1 GUWXKKAWLCENJA-WGWHJZDNSA-N 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- GYQYAJJFPNQOOW-UHFFFAOYSA-N gilteritinib Chemical compound N1=C(NC2CCOCC2)C(CC)=NC(C(N)=O)=C1NC(C=C1OC)=CC=C1N(CC1)CCC1N1CCN(C)CC1 GYQYAJJFPNQOOW-UHFFFAOYSA-N 0.000 description 1
- 229950006304 gilteritinib Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229950007752 isatuximab Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical group CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229950010895 midostaurin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 201000006039 nodal marginal zone lymphoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- BNJNAEJASPUJTO-DUOHOMBCSA-N vadastuximab talirine Chemical group COc1ccc(cc1)C2=CN3[C@@H](C2)C=Nc4cc(OCCCOc5cc6N=C[C@@H]7CC(=CN7C(=O)c6cc5OC)c8ccc(NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CCCCCN9C(=O)C[C@@H](SC[C@H](N)C(=O)O)C9=O)C(C)C)cc8)c(OC)cc4C3=O BNJNAEJASPUJTO-DUOHOMBCSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562188404P | 2015-07-02 | 2015-07-02 | |
| US62/188,404 | 2015-07-02 | ||
| US201562245916P | 2015-10-23 | 2015-10-23 | |
| US62/245,916 | 2015-10-23 | ||
| US201662308055P | 2016-03-14 | 2016-03-14 | |
| US62/308,055 | 2016-03-14 | ||
| US201662340972P | 2016-05-24 | 2016-05-24 | |
| US62/340,972 | 2016-05-24 | ||
| PCT/US2016/040718 WO2017004532A1 (en) | 2015-07-02 | 2016-07-01 | Combination therapy for treatment of hematological cancers and solid tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020112519A Division JP2020172502A (ja) | 2015-07-02 | 2020-06-30 | 血液がん及び固形腫瘍の治療のための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018524347A JP2018524347A (ja) | 2018-08-30 |
| JP2018524347A5 true JP2018524347A5 (https=) | 2019-08-15 |
| JP6727237B2 JP6727237B2 (ja) | 2020-07-22 |
Family
ID=56418624
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568243A Expired - Fee Related JP6727237B2 (ja) | 2015-07-02 | 2016-07-01 | 血液がん及び固形腫瘍の治療のための併用療法 |
| JP2020112519A Pending JP2020172502A (ja) | 2015-07-02 | 2020-06-30 | 血液がん及び固形腫瘍の治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020112519A Pending JP2020172502A (ja) | 2015-07-02 | 2020-06-30 | 血液がん及び固形腫瘍の治療のための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10973822B2 (https=) |
| EP (1) | EP3316888A1 (https=) |
| JP (2) | JP6727237B2 (https=) |
| KR (1) | KR20180023968A (https=) |
| AU (1) | AU2016288246A1 (https=) |
| BR (1) | BR112017028530A2 (https=) |
| CA (1) | CA2991164A1 (https=) |
| EA (1) | EA201890199A1 (https=) |
| MX (1) | MX2018000216A (https=) |
| WO (1) | WO2017004532A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070606A1 (en) | 2015-10-21 | 2017-04-27 | Teclison Limited | Compositions and methods for immune-mediated cancer therapy |
| CA3006758A1 (en) | 2015-12-02 | 2017-06-08 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| US12358983B2 (en) | 2016-10-28 | 2025-07-15 | Incyte Corporation | Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof |
| CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| US12064436B2 (en) | 2017-06-12 | 2024-08-20 | Servier Pharmaceuticals Llc | Methods of treating brain tumors using combination therapy |
| CA3067035A1 (en) | 2017-06-12 | 2018-12-20 | Agios Pharmaceuticals, Inc. | Methods of treating brain tumors using combination therapy |
| MX2020003395A (es) * | 2017-10-13 | 2020-08-03 | Merck Sharp & Dohme | Composiciones y metodos para tratar linfoma difuso de celulas b grandes. |
| US20230132400A9 (en) * | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
| CA3107186A1 (en) * | 2018-07-30 | 2020-02-06 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
| EP3974455A4 (en) * | 2019-05-21 | 2023-06-14 | Kuraray Noritake Dental Inc. | RESIN COMPOSITION FOR OPTICAL THREE-DIMENSIONAL MODELING |
| WO2021041669A1 (en) * | 2019-08-30 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Immune signatures predictive of response to pd-1 blockade in richter's transformation |
| US11839619B2 (en) * | 2019-09-16 | 2023-12-12 | The Regents Of The University Of California | Methods for treatment of pediatric systemic mastocytosis |
| WO2021092190A1 (en) * | 2019-11-05 | 2021-05-14 | Health Research, Inc. | Combination therapy for cancer |
| EP4073517A1 (en) * | 2019-12-11 | 2022-10-19 | Erasmus University Rotterdam Medical Center | Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias |
| US20220117929A1 (en) * | 2020-10-21 | 2022-04-21 | Buddhist Tzu Chi Medical Foundation | Method for preventing or treating high-grade serous carcinoma |
| US12523658B2 (en) * | 2021-08-27 | 2026-01-13 | The Board Of Regents Of The University Of Texas System | Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications |
| CA3224890A1 (en) * | 2021-10-29 | 2023-05-04 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for hematological cancer |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| CN115137731B (zh) * | 2022-05-19 | 2023-11-21 | 上海交通大学医学院附属新华医院 | Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| ME02420B (me) | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| DK2683708T3 (da) | 2011-03-11 | 2018-01-29 | Celgene Corp | Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf |
| PH12013501837A1 (en) * | 2011-03-11 | 2013-11-18 | Celgene Corp | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
| EP2892887B1 (en) | 2012-09-04 | 2020-07-15 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| EP2892537A1 (en) * | 2012-09-10 | 2015-07-15 | Celgene Corporation | Methods for the treatment of locally advanced breast cancer |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| SMT201700513T1 (it) | 2013-05-01 | 2018-01-11 | Celgene Corp | Sintesi di 3-(5-ammino-2-metil-4-ossochinazolin-3(4h)-il) piperidin-2,6-dione |
| EP2991651A1 (en) * | 2013-05-03 | 2016-03-09 | Celgene Corporation | Methods for treating cancer using combination therapy |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| TW201540323A (zh) | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| KR20170029565A (ko) | 2014-07-11 | 2017-03-15 | 셀진 코포레이션 | 암 치료를 위한 병용요법 |
| CA2996641A1 (en) | 2015-08-27 | 2017-03-02 | Celgene Corporation | Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| CA3006758A1 (en) | 2015-12-02 | 2017-06-08 | Celgene Corporation | Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
-
2016
- 2016-07-01 US US15/741,130 patent/US10973822B2/en not_active Expired - Fee Related
- 2016-07-01 WO PCT/US2016/040718 patent/WO2017004532A1/en not_active Ceased
- 2016-07-01 EA EA201890199A patent/EA201890199A1/ru unknown
- 2016-07-01 KR KR1020187002705A patent/KR20180023968A/ko not_active Withdrawn
- 2016-07-01 EP EP16739642.3A patent/EP3316888A1/en not_active Withdrawn
- 2016-07-01 CA CA2991164A patent/CA2991164A1/en not_active Abandoned
- 2016-07-01 JP JP2017568243A patent/JP6727237B2/ja not_active Expired - Fee Related
- 2016-07-01 BR BR112017028530A patent/BR112017028530A2/pt not_active Application Discontinuation
- 2016-07-01 AU AU2016288246A patent/AU2016288246A1/en not_active Abandoned
- 2016-07-01 MX MX2018000216A patent/MX2018000216A/es unknown
-
2020
- 2020-06-30 JP JP2020112519A patent/JP2020172502A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018524347A5 (https=) | ||
| JP2017506227A5 (https=) | ||
| JP2020172502A5 (https=) | ||
| JP2023058502A (ja) | 抗ｃｄ１９抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 | |
| JP2019517485A5 (https=) | ||
| JP2019506403A5 (https=) | ||
| CN111918652A (zh) | 用于治疗eb病毒阳性的癌症的趋化因子受体调节剂 | |
| Wu et al. | Novel agents for chronic lymphocytic leukemia | |
| US20250195646A1 (en) | Combinations and uses thereof | |
| JP2020505433A5 (https=) | ||
| JP2008530142A5 (https=) | ||
| JP2017530950A5 (https=) | ||
| BR112013006769B1 (pt) | combinação sinérgica | |
| JP2014510729A5 (https=) | ||
| CN109640999A (zh) | 组合疗法 | |
| JP6184952B2 (ja) | 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 | |
| JP2017515802A5 (https=) | ||
| CN107073122A (zh) | 恶性肿瘤的联合治疗 | |
| JP2022137089A (ja) | 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 | |
| JP2018503610A5 (https=) | ||
| JP2014525926A5 (https=) | ||
| JP2013511487A (ja) | Ｃｄｃ７阻害剤と抗新生物薬とを含む治療用の組み合わせ | |
| AU2012296907A1 (en) | Combination therapy with an anti - CD19 antibody and a nitrogen mustard | |
| JP2015517512A5 (https=) | ||
| JP2020531414A5 (https=) |